Consolidated Total Revenue: ₹1,019.4 crores (QoQ: ₹794 crores in Q1FY27; YoY: ₹1,463 crores in Q2FY26).
EBITDA including other income: ₹310 crores.
EBITDA Margin: 30.4%.
Consolidated Profit After Tax (PAT): ₹202.6 crores (QoQ: ₹206.5 crores in Q1FY27).
The quarter-on-quarter revenue increase was primarily driven by strong performance in the international formulation business. The year-on-year decline was largely attributable to lower lenalidomide revenue, partially offset by growth in the base business including subsidiaries.
Associate Company - Adcock Ingram Holding Limited (South Africa)
Revenue for the quarter: ₹1,344 crores.
Profit After Tax for the quarter: ₹80.5 crores.
In July 2026, NATCO acquired an additional 13.25% stake in Adcock Ingram, taking its total holding to 49%.
NATCO's share of profit based on 49% holding as of 30 September 2026 was ₹29.2 crores, after adjustment for purchase price allocation.
A dividend of ₹78 crores was received from Adcock during the period.
The company estimates a steady-state annual PAT contribution from its 49% stake to be approximately ₹55-60 crores, after accounting for amortization.
Segment-wise Performance
Domestic Formulation Business Revenue: ₹145 crores. The management clarified that the base domestic run rate is ₹130-135 crores, with the higher Q2 figure including a one-time stocking quantity of Semaglutide for partners.
Brazil Business Revenue: ₹121 crores, representing 66% growth.
Crop Health Sciences (Agri-business): Reported a marginal profit of ~₹10 lakhs for the quarter, compared to a loss in Q1. The business is battling credit-related provisions and El Niño effects but expects 15-20% growth for the year.
Capital Structure & Fundraising
A rights issue was completed last month (October 2026), resulting in a 10% equity dilution.
The primary end-use of the proceeds is to reduce debt raised for the Adcock acquisition and to fund potential future acquisitions.
As of the call date, the company reported net cash of approximately ₹2,250 crores after repaying all debt.
A dividend was declared, consistent with the company's historical policy, and is not linked to the recent fundraising.
Guidance & Outlook
Management provided FY27 PAT guidance of ₹775-800 crores, an improvement over the initial guidance of ₹700-750 crores.
The guidance includes an expected EBITDA loss of ~₹20 crores from the Crop Health Sciences segment.
The base business (excluding one-time exclusivity gains) is expected to grow at 10-15% in FY28.
R&D spend for FY27 is expected to be 8-10% of sales, amounting to approximately ₹300-350 crores.
Annual Capex run rate is typically ₹350-400 crores, focused on upgrading facilities in Chennai, Mekaguda, and Nagarjuna Sagar, including a new oncology line and a cartridge line for internal Semaglutide production.
Product Pipeline & Launches
Pomalidomide: Had a shared first-to-file (FTF) status with 5-6 competitors. The price erosion was steep, resulting in a less substantial earnings bump than anticipated.
Upcoming US Launches (Subject to approval and legal challenges): Carfilzomib (60mg strength has shared FTF; one lower strength has sole FTF), Trabectedin (one of two FTFs), and Olaparib (for Brazil and Canada).
Semaglutide (India): The company has an estimated 5-6% volume share and ~3% value share in the Indian market. Pricing is described as "really bad" due to intense competition, and the business is not currently profitable.
Other Products: Risdiplam is performing well domestically. The US filing for Semaglutide is ongoing, with queries being answered. Imbruvica is settled and approved for launch in 30 months.
NRC-2694: Phase-I data is complete; the company is re-evaluating its Phase-II strategy. No commercialization timeline provided.
Strategic Updates
Adcock Ingram: A new CEO, Mr. Rhulani (ex-Pfizer), has been appointed to strengthen the prescription business. The company has filed multiple products for regulatory approval in South Africa, with launches expected in the next 1.5-2 years.
Crop Health Sciences Demerger: The process has been delayed by 4-6 months due to the recent rights issue altering the capital structure. The company must resubmit filings to SEBI and now expects the demerger to be completed by mid-calendar year 2027.
Acquisition Strategy: The company is actively looking for acquisition opportunities and is in serious discussions for one transaction. The strategy focuses on "value for money" rather than a specific target P/E.
Investment in eGenesis: NATCO holds a substantial single-digit stake (investment <$25 million) in eGenesis, a company developing xenotransplantation (pig-to-human kidney transplant). Monetization options include securing a license for the India market or an eventual IPO of eGenesis. Data readouts are expected in the next 12 months.
Management Commentary
The CEO, Mr. Rajeev Nannapaneni, addressed concerns about the company's stock performance and P/E multiple, characterizing NATCO's model as "high-risk, high-return" with inherent earnings lumpiness due to exclusivity-driven revenues.
He emphasized that communication with investors is regular and that the company's strategy remains focused on creating long-term value through strategic investments and pipeline development, rather than managing short-term stock price movements.